Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Frenkel

Showing results (371-380 of 383) with videos related to

Pageof 39
Sort By:
Cell Reports. Medicine|May 5, 2021
A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoirClaire N Levy, Sean M Hughes, Pavitra Roychoudhury, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineMarc Lallemant, Nicole Ngo-Giang-Huong, Gonzague Jourdain, et al.
The Lancet. HIV|May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trialLameck Chinula, Lauren Ziemba, Sean Brummel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2025
HIV resistance to dolutegravir varies with co-administered agentsIngrid A Beck, Ceejay L Boyce, Marley D Bishop, et al.
Science (New York, N.Y.)|June 6, 1998
Genetic evaluation of suspected cases of transient HIV-1 infection of infantsL M Frenkel, J I Mullins, G H Learn, et al.
The Lancet. Infectious Diseases|December 5, 2017
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysisRavindra K Gupta, John Gregson, Neil Parkin, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
The New England Journal of Medicine|October 14, 2011
Oral acyclovir suppression and neurodevelopment after neonatal herpesDavid W Kimberlin, Richard J Whitley, Wen Wan, et al.
Lancet (London, England)|April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trialShahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
Plos One|December 31, 2015
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingSoo-Yon Rhee, Michael R Jordan, Elliot Raizes, et al.
Pageof 39

Showing results (371-380 of 383) with videos related to

Sort By:
Pageof 39
Cell Reports. Medicine|May 5, 2021
A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoirClaire N Levy, Sean M Hughes, Pavitra Roychoudhury, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineMarc Lallemant, Nicole Ngo-Giang-Huong, Gonzague Jourdain, et al.
The Lancet. HIV|May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trialLameck Chinula, Lauren Ziemba, Sean Brummel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2025
HIV resistance to dolutegravir varies with co-administered agentsIngrid A Beck, Ceejay L Boyce, Marley D Bishop, et al.
Science (New York, N.Y.)|June 6, 1998
Genetic evaluation of suspected cases of transient HIV-1 infection of infantsL M Frenkel, J I Mullins, G H Learn, et al.
The Lancet. Infectious Diseases|December 5, 2017
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysisRavindra K Gupta, John Gregson, Neil Parkin, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
The New England Journal of Medicine|October 14, 2011
Oral acyclovir suppression and neurodevelopment after neonatal herpesDavid W Kimberlin, Richard J Whitley, Wen Wan, et al.
Lancet (London, England)|April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trialShahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
Plos One|December 31, 2015
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingSoo-Yon Rhee, Michael R Jordan, Elliot Raizes, et al.
Pageof 39